Recombinant Mouse CD229/SLAMF3 protein (His Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg1586



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Mouse CD229 protein Lys48-Arg453 (Accession# Q01965) with a His tag at the C-terminus.
GeneID 17085
Accession Q01965
PredictedSize 46.2 kDa
SDS-PAGE 60-70 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Signaling lymphocytic activation molecule 3 (SLAMF3), also known as CD229 or Ly9, is a type I transmembrane glycoprotein that belongs to the SLAM family receptors. It is composed of an extracellular region, which consists of four Ig-like domains, a transmembrane region, and a cytoplasmic tail, which includes two immunoreceptor tyrosine-based signaling motifs (ITSMs) and other tyrosine residues that act as binding sites for the SH2 structural domains. SLAMF3 is mainly expressed in immune cells, such as T, B, and natural killer cells, and it is involved in the fundamental activation and suppression of these immune cells, as well as the regulation of complex immune networks.

References:

1.Tovar V, et al. (2000) Immunogenetics. 51(10):788-93. 2.Romero X, et al. (2005) J Immunol. 174(11):7033-42. 3.Sandrin MS, et al. (1996) Immunogenetics. 43(1-2):13-9. 4.de la Fuente MA, et al. (2001) Blood. 97(11):3513-20. 5.Zhou T, et al. (2024) Int Immunopharmacol. 133:112088.